![DiaMedica Therapeutics Inc. logo](/logos/DMAC.webp)
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Overview | Financials
Company Name | DiaMedica Therapeutics Inc. |
Symbol | DMAC |
Currency | USD |
Price | 4.03 |
Market Cap | 172,273,634 |
Dividend Yield | 0% |
52-week-range | 1.938 - 4.07 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Dietrich John Pauls MBA |
Website | https://www.diamedica.com |
An error occurred while fetching data.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD